Kiguchi Norikazu, Maeda Takehiko, Kobayashi Yuka, Saika Fumihiro, Kishioka Shiroh
Department of Pharmacology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan.
Int Rev Neurobiol. 2009;85:179-90. doi: 10.1016/S0074-7742(09)85014-9.
Elucidation of the mechanism of neuropathic pain caused by vincristine is required because long-term treatment with this anticancer agent often causes neuropathic pain. We refer to the involvement of inflammatory mediators in vincristine-induced neuropathic pain in this review. Several reports using rodents have shown that long-lasting neuropathic pain (mechanical allodynia) is caused by repeated systemic injection of vincristine. Vincristine damaged Schwann cells and DRG neurons in this model. Vincristine-induced macrophage infiltration in the peripheral nervous system (PNS) and macrophage-derived IL-6 elicited mechanical allodynia. These findings proved that inhibition of IL-6 function prevented neuropathic pain caused by vincristine. In the central nervous system (CNS), activation of microglia and astrocytes in the spinal cord were demonstrated after long-term vincristine treatment. TNF-alpha was upregulated in activated microglia and astrocytes, and inhibition of TNF-alpha function attenuated neuropathic pain caused by vincristine. These results suggest that vincristine induces macrophage infiltration to the damaged PNS, and that macrophage-derived inflammatory cytokines such as IL-6 elicits neuroinflammation. Signal transduction of pain from the PNS to the CNS activates microglia and astrocytes, and these activated glial cells release inflammatory cytokines such as TNF-alpha. In the CNS, these inflammatory cytokines have an important role in the neuropathic pain caused by vincristine. Immune-modulating agents that prevent activation of immune cells and/or the inhibitory agents of inflammatory cytokines could prevent the neuropathic pain caused by vincristine. These agents could increase the tolerability of vincristine when used for the treatment of leukemia and lymphoma.
由于长期使用这种抗癌药物常导致神经性疼痛,因此需要阐明长春新碱引起神经性疼痛的机制。在本综述中,我们探讨了炎症介质在长春新碱诱导的神经性疼痛中的作用。几项使用啮齿动物的报告表明,反复全身注射长春新碱会导致持久的神经性疼痛(机械性异常性疼痛)。在该模型中,长春新碱损害了雪旺细胞和背根神经节神经元。长春新碱诱导外周神经系统(PNS)中的巨噬细胞浸润,且巨噬细胞衍生的白细胞介素-6引发了机械性异常性疼痛。这些发现证明,抑制白细胞介素-6的功能可预防长春新碱引起的神经性疼痛。在中枢神经系统(CNS)中,长期使用长春新碱治疗后,脊髓中的小胶质细胞和星形胶质细胞被激活。肿瘤坏死因子-α(TNF-α)在激活的小胶质细胞和星形胶质细胞中上调,抑制TNF-α的功能可减轻长春新碱引起的神经性疼痛。这些结果表明,长春新碱诱导巨噬细胞浸润到受损的PNS,且巨噬细胞衍生的炎症细胞因子如白细胞介素-6引发神经炎症。从PNS到CNS的疼痛信号转导激活了小胶质细胞和星形胶质细胞,这些激活的神经胶质细胞释放炎症细胞因子如TNF-α。在CNS中,这些炎症细胞因子在长春新碱引起的神经性疼痛中起重要作用。预防免疫细胞激活的免疫调节剂和/或炎症细胞因子的抑制剂可预防长春新碱引起的神经性疼痛。这些药物在用于治疗白血病和淋巴瘤时可提高长春新碱的耐受性。